Multitargeted low-dose GLAD combination chemoprevention: A novel and promising approach to combat colon carcinogenesis

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 481-490

  Mohammed, Altaf ^a   Janakiram, Naveena B ^a   Brewer, Misty ^a   Vedala, Krishna ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA CATENIN; CASPASE 3; CAVEOLIN 1; CHEMOKINE; CYTOKINE; EFLORNITHINE; GEFITINIB; LICOFELONE; LIVER ENZYME; PROTEIN P21; ANTINEOPLASTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREEDING; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; DENSITOMETRY; DIET; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; LOW DRUG DOSE; MALE; MOLECULAR MECHANICS; NICK END LABELING; NONHUMAN; POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADENOMATOUS POLYPS; ANIMAL; BLOOD; C57BL MOUSE; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; SMALL INTESTINE; TRANSGENIC MOUSE;

ADENOMATOUS POLYPS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPREVENTION; COLON; COLONIC NEOPLASMS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EFLORNITHINE; FEMALE; HEPTANOIC ACIDS; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PYRROLES; QUINAZOLINES;

EID: 84877070255     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13282     Document Type: Article

References (50)

1. American Cancer Society (2013). Cancer Facts and Figures 2013. American Cancer Society, Atlanta, GA.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2010). GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. International Agency for Research on Cancer, Lyon, France, Available at: http://globocan.iarc.fr.
3. Half E and Arber N (2009). Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 10, 211-219.
4. Moser AR, Pitot HC, and Dove WF (1990). A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322-324.
5. Preston SL, Leedham SJ, Oukrif D, Deheregoda M, Goodlad RA, Poulsom R, Alison MR, Wright NA, and Novelli M (2008). The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol 214, 294-301.
6. Corpet DE and Pierre F (2003). Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12, 391-400.
7. Reddy BS and Rao CV (2002). Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 21, 155-164.
8. Reddy BS, Hirose Y, Lubet R, Steele V, Kellof G, Paulson S, Seibert K, and Rao CV (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60, 293-297.
9. Kawamori T, Rao CV, Seibert K, and Reddy BS (1998). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58, 409-412.
10. Swamy MV, Herzog CR, and Rao CV (2000). Celecoxib inhibition of COX-2 in colon cancer cell lines increases the nuclear localization of functionally active p53. Cancer Res 63, 5239-5242.
11. Rao CV, Wang CQ, Simi B, Rodriguez JG, Cooma I, El-Bayoumy K, and Reddy BS (2001). Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res 61, 3647-3652.
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, et al. (2009). Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2, 310-321.
13. Min/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res (Phila) 4(12), 2015-2026.
14. Min/+ mice. Neoplasia 14(2), 159-168.
15. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, et al. (2012). Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 48(9), 887-892.
16. Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG, Viner JL, Spechler SJ, Hawk ET, and Brenner DE (2004). Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 13(7), 1250-1252.
17. Zhou P, Cheng SW, Yang R, Wang B, and Liu J (2012). Combination chemoprevention: future direction of colorectal cancer prevention. Eur J Cancer Prev 21(3), 231-240.
18. Gerner EW and Meyskens FL (2009). Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15(3), 758-761.
19. Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Janakiram NB, et al. (2011). Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila) 4(11), 1895-1902.
20. Sporn MB (1980). Combination chemoprevention of cancer. Nature 287, 107-108.
21. Frei E III (1972). Combination cancer therapy: presidential address. Cancer Res 32, 2593-2607.
22. Nigro ND, Bull AW, and Boyd ME (1986). Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 77, 1309-1313.
23. 2 levels in rat colon. Carcinogenesis 20, 425-430.
24. Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, and Anton-Culver H (2007). Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 120, 459-468.
25. Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, and Gerner EW (2008). Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60(1), 30-35.
26. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008). Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1, 32-38.
27. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, and Rao CV (2006). Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66(8), 4542-4546.
28. Ali S, El-Rayes BF, Sarkar FH, and Philip PA (2005). Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4(12), 1943-1951.
29. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, and Aizawa R (1996). Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor, of N -methyl-N -nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87, 798-804.
30. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M, and Aizawa R (1996). Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 180, 131-138.
31. Poynter JN, Rennert G, Bonner JD, Rennert HS, Greenson JK, and Gruber SB (2004). HMG-CoA reductase inhibitors and the risk of colorectal cancer. Proc Am Soc Clin Oncol 23, 1.
32. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335, 1001-1009.
33. Pederson TR, Berge K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyörälä K., et al. (1996). Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156, 2085-2092.
34. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, and Holt PR (1999). Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117, 838-847.
35. Min mice. Cancer Res 66(14), 7370-7377.
36. min/+ mouse. Br J Cancer 105, 649-657.
37. Gavert N and Ben-Ze'ev A (2007). β-Catenin signaling in biological control and cancer. J Cell Biochem 102, 820-828.
38. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20, 4292-4302.
39. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, and Lubet RA (2000). Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60(7), 1864-1870.
40. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, and Gerner EW (1999). APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20(9), 1709-1713.
41. Min/+ mice. Mol Carcinog 45(10), 764-773.
42. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, et al. (2008). Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 14(8), 2253-2262.
43. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, Michalski W, and Chechlinska M (2005). Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I-an independent prognostic factor. Tumor Biol 26, 186-194.
44. Ueda T, Shimada E, and Urakawa T (1994). Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29, 423-429.
45. α and Wnt/β-catenin pathways during colorectal tumorigenesis. Oncogene 25, 3065-3070.
46. Harris RE (2007). Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42, 93-126.
47. Fantini MC and Pallone F (2008). Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 9, 375-380.
48. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, and Ellis LM (1999). Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1β. Br J Cancer 80, 1506-1511.
49. Petersen AM and Pedersen BK (2005). The anti-inflammatory effect of exercise. J Appl Physiol 98, 1154-1162.
50. Lee JJ, Liebermane R, Sloand JA, Piantadosic S, and Lippman SM (2001). Design considerations for efficient prostate cancer chemoprevention trials. Urology 57(4), 205-212.